RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients

Table 3

Comparison of KRAS gene mutation in ctDNA and tumor tissue.

Plasma	Synchronous group tumor			Metachronous group tumor			Total	Sensitivity (%)	Specificity (%)	Concordance (%)
	Mt	Wt	NA	Mt	Wt	NA
Mt	4	2	1	12	2	2	23	66.67%	90.00%	81.25%
Wt	2	14	5	6	22	4	53
Total	6	16	6	18	24	6	76

Note. Mt, mutate type; Wt, wild type; NA, not available.